Table 1.
Demographics and clinical characteristics of the study population, overall and by treatment group.
| Characteristics | Overall n = 111 |
Cefiderocol n = 60 |
Colistin n = 51 |
p-Value | ||
|---|---|---|---|---|---|---|
| Age, years, median (IQR) | 69 (59–78) | 62 (48–75) | 72 (64–81) | <0.001 | ||
| Gender, male, n (%) | 75 (68) | 38 (63) | 37 (73) | 0.300 | ||
| Number of comorbidities, median (IQR) | 3 (2–4) | 2.4 (1–4) | 3 (2–4) | 0.067 | ||
| Coinfections, n (%) | COVID-19 | 36 (32) | 16 (27) | 20 (39) | 0.160 | |
| Gram-positive infection | 22 (19.8) | 11 (18.3) | 11 (21.6) | 0.670 | ||
| Candidemia | 7 (6.3) | 5 (8.3) | 2 (3.9) | 0.340 | ||
| Comorbidities, n (%) | Cardiovascular disease | 73 (66) | 35 (58) | 38 (75) | 0.073 | |
| Diabetes | 27 (24) | 10 (17) | 17 (33) | 0.041 | ||
| Obesity | 41 (37) | 16 (27) | 25 (49) | 0.015 | ||
| Lung disease | 30 (27) | 20 (33) | 10 (20) | 0.100 | ||
| Chronic kidney disease | 18 (16) | 12 (22) | 5 (10) | 0.091 | ||
| Psychiatric disorders | 43 (39) | 20 (33) | 23 (45) | 0.100 | ||
| Malignancy | 19 (17) | 9 (15) | 10 (20) | 0.520 | ||
| Type of infection, n (%) | Bloodstream infection | 53 (47.7) | 34 (56.6) | 19 (37.2) | 0.003 | |
| Pneumonia | 58 (52.3) | 26 (43.4) | 32 (62.8) | |||
| Length of stay, days, median (IQR) | 45 (24–70) | 52 (32–73) | 34 (20–72) | 0.023 | ||
| Ward of admission, n (%) | Medical | 51 (46) | 22 (27) | 29 (57) | 0.087 | |
| Surgery | 25 (23) | 17 (28) | 8 (16) | |||
| ICU | 35 (32) | 21 (25) | 14 (27) | |||
| CVVH, n (%) | 5 (4.5) | 4 (6.6) | 1 (1.9) | 0.23 | ||
| ECMO, n (%) | 3 (2.7) | 3 (5) | 0 (0) | 0.1 | ||
| Mechanical ventilation, n (%) | 22 (20) | 13 (22) | 9 (18) | 0.6 | ||
| SOFA score, median (IQR) | 2.5 (1–4.2) | 3.5 (2–5) | 2 (1–4) | 0.072 | ||
| APACHE score, median (IQR) | 10 (7–13) | 10 (7.8–13.2) | 10 (7–13) | 0.890 | ||
| C-reactive protein, mg/dl, median (IQR) | 104 (66–160) | 97 (67–160) | 110 (61–162) | 0.880 | ||
| Procalcitonin, ng/mL, median (IQR) | 0.74 (0.16–3) | 0.52 (0.13–1.65) | 1.1 (0.2–5.1) | 0.270 | ||
| White blood count, median (IQR) | 11.9 (7.6–17.6) | 11.8 (7.3–17.6) | 11.9 (7.8–17.6) | 0.830 | ||
| Creatinine, mmol/L, median (IQR) | 69 (44–101) | 64 (36–88) | 77 (52–118) | 0.042 | ||
| Acute kidney injury, n (%) | 19 (17.1) | 6 (10) | 13 (25.5) | 0.031 | ||
| Study outcomes | Clinical cure, n (%) | 78 (70) | 44 (73) | 34 (67) | 0.440 | |
| Microbiological cure, n (%) | 47 (42) | 26 (43) | 21 (41) | 0.820 | ||
| Deaths, n (%) | 48 (43) | 26 (51) | 22 (37) | 0.130 | ||
Legend for Table 1: n = number, % = percentage, IQR = interquartile range, ICU = intensive care unit, SOFA = sequential organ failure assessment, APACHE= acute physiological assessment of chronic health evaluation, CVVH = continuous venovenous hemofiltration, ECMO = extracorporeal membrane oxygenation.